Format

Send to

Choose Destination
Growth Horm IGF Res. 2007 Feb;17(1):54-7. Epub 2006 Dec 12.

Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report.

Author information

1
Endocrinology and Diabetes Research Unit, Schneider Children's Medical Center, 14 Kaplan Street, Petah-Tikva 49202, Israel.

Abstract

OBJECTIVE:

Overexpression of IGF-I occurs in tumors diagnosed in childhood (osteosarcoma, Wilms tumor, neuroblastoma, etc.) and in adults (breast, ovaries, colon and prostate cancer). The aim of our study was to establish the prevalence of malignancies in states of congenital IGF-I deficiency.

SUBJECTS:

We surveyed 222 patients with congenital IGF-I deficiency (Laron syndrome, GH gene deletion, GHRH receptor defects and IGF-I resistance) and 338 first and second-degree relatives.

RESULTS:

None of the IGF-I deficient patients had cancer, whereas 9-24% of the family members had a history of malignancy.

CONCLUSIONS:

Congenital IGF-I deficiency acts as a protecting factor for the development of cancer.

PMID:
17166755
DOI:
10.1016/j.ghir.2006.10.007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center